crizotinib
ApprovedActive 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
NSCLC
Conditions
NSCLC, ALCL, IMT
Trial Timeline
Dec 27, 2021 → Mar 21, 2028
NCT ID
NCT05160922About crizotinib
crizotinib is a approved stage product being developed by Pfizer for NSCLC. The current trial status is active. This product is registered under clinical trial identifier NCT05160922. Target conditions include NSCLC, ALCL, IMT.
What happened to similar drugs?
6 of 20 similar drugs in NSCLC were approved
Approved (6) Terminated (3) Active (12)
Hype Score Breakdown
Clinical
20
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03085186 | Pre-clinical | Completed |
| NCT02473497 | Pre-clinical | Completed |
| NCT02824094 | Pre-clinical | Completed |
| NCT05160922 | Approved | Active |
| NCT04084717 | Phase 2 | Recruiting |
| NCT03672643 | Approved | Terminated |
| NCT03088930 | Phase 2 | Completed |
| NCT03375242 | Pre-clinical | Recruiting |
| NCT02612194 | Phase 2 | Terminated |
| NCT02679170 | Pre-clinical | Completed |
| NCT02223819 | Phase 2 | Completed |
| NCT02270034 | Phase 1 | Completed |
| NCT01500824 | Phase 2 | Withdrawn |
| NCT02183870 | Phase 2 | Completed |
| NCT01945021 | Phase 2 | Completed |
| NCT02034981 | Phase 2 | Completed |
| NCT01121588 | Phase 1 | Terminated |
| NCT01297595 | Phase 1 | Completed |
| NCT01154218 | Phase 1 | Completed |
| NCT01125904 | Phase 1 | Completed |
Competing Products
20 competing products in NSCLC